NCT06678555Completed
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
A RETROSPECTIVE STUDY TO EVALUATE THE REAL-WORLD EFFECTIVENESS OF LORLATINIB AMONG ROS1-POSITIVE NSCLC PATIENTS
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled. This study is seeking participants who: * have lung cancer that could not be controlled. * have a type of gene called a ROS proto-oncogene 1. A gene is a part of your DNA that has instructions for making things your body needs to work. * have received at least 1 treatment before. All participants in this study had received lorlatinib. Lorlatinib is a tablet that is taken by mouth at home. They continued to take lorlatinib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 22 (actual)
- First submitted
- 5 Nov 2024
- Start date
- 4 Jul 2025
- Primary completion date
- 14 Apr 2026
- Lead sponsor
- Pfizer
- Diseases
- Lung cancer
- NCT number
- NCT06678555
What you commit to
- Study type: Observational
- Participants enrolled: 22
- From 4 Jul 2025 to the primary completion date, 14 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Patients participated in any clinical trials using lorlatinib during the observation period.
Who the study is looking for
- Patients are aged 18 years or older on index date
- Patients have confirmed diagnosis of ROS1-positive NSCLC
- Patients have received at least one dose of lorlatinib between 1st April, 2018, and 30th September, 2023
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.